Insulin isophane human and insulin human - Biologic Drug Details

Summary for insulin isophane human and insulin human

Tradenames:	2
High Confidence Patents:	2
Applicants:	2
BLAs:	2
Suppliers: see list	3

Pharmacology for insulin isophane human and insulin human

Established Pharmacologic Class	Insulin
Chemical Structure	Insulin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for insulin isophane human and insulin human Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for insulin isophane human and insulin human Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novo Nordisk Inc.	NOVOLIN 70/30	insulin isophane human and insulin human	Injection	019991	4,973,318	2009-02-09	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	NOVOLIN 70/30	insulin isophane human and insulin human	Injection	019991	5,462,535	2014-10-14	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for insulin isophane human and insulin human Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Eli Lilly And Company	HUMULIN 70/30	insulin isophane human and insulin human	Injectable Suspension	019717	10,660,941	2037-02-17	Patent claims search
Novo Nordisk Inc.	NOVOLIN 70/30	insulin isophane human and insulin human	Injection	019991	10,016,338	2036-12-20	Patent claims search
Novo Nordisk Inc.	NOVOLIN 70/30	insulin isophane human and insulin human	Injection	019991	10,577,154	2038-12-19	Patent claims search
Novo Nordisk Inc.	NOVOLIN 70/30	insulin isophane human and insulin human	Injection	019991	10,660,941	2037-02-17	Patent claims search

International Patents for insulin isophane human and insulin human

Country	Patent Number	Estimated Expiration
China	1035055
World Intellectual Property Organization (WIPO)	8907463
Germany	787502
Spain	2030541

Insulin isophane human and insulin human Market Analysis and Financial Projection

Last updated: February 15, 2026

Market Dynamics and Financial Trajectory for Insulin Isophane Human and Insulin Human

What Is the Market Size and Growth Outlook for These Insulins?

The global insulin market, valued at approximately $25.5 billion in 2022, is projected to reach $63.6 billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 12%. Insulin isophane human (NPH) and insulin human constitute a significant portion of this market, accounting for nearly 45% of total insulin sales, with annual revenues in 2022 estimated around $11.5 billion. The growth is driven by increasing prevalence of diabetes mellitus, especially Type 1 and Type 2, and expanding access in emerging markets.

How Do Market Dynamics Drive Demand and Competition?

Pricing pressure and biosimilar entry: Patent expirations for key insulin formulations, such as Humulin N (Eli Lilly) and Novolin N (Novo Nordisk), occurred in 2015-2018, opening pathways for biosimilar entrants. Biosimilars generally offer a 20-30% price reduction, leading to increased volume sales but exerting downward pressure on premium pricing of innovator products.

Regulatory environment: The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) streamline pathways for biosimilar approvals, reducing development timelines from 8-10 years to approximately 5-7 years, depending on data requirements. This accelerates market entry for generic-like insulin products.

Manufacturing complexities: Insulin's protein nature requires specialized bioprocessing, which increases manufacturing costs. Innovations in recombinant DNA technology have lowered production costs but securing consistent quality remains a regulatory challenge, influencing pricing strategies.

Emerging markets: Countries such as China, India, and Brazil exhibit rapid growth, driven by increasing healthcare infrastructure and government initiatives to boost diabetes management access. For example, China's insulin market is expected to grow at a CAGR of 8.5% through 2027, with local production capacities expanding.

Therapeutic preferences: Long-acting insulins (e.g., insulin glargine) and rapid-acting insulins dominate the high-margin segment, but NPH and regular insulin remain essential due to their lower cost and established use in resource-limited settings.

What Are the Financial Trends for Insulin Isophane Human and Insulin Human?

Revenue streams: Leading players like Novo Nordisk, Eli Lilly, and Sanofi report combined insulin revenues exceeding $20 billion annually, with NPH and human insulin contributing approximately $5-6 billion of this figure. Sales are declining slowly for patented analog insulins but remain stable for human insulins, due to cost-sensitive markets.

Pricing trends: In the U.S., list prices for NPH have declined from approximately $120 per vial in 2015 to around $80 per vial in 2022, with net prices shrinking further after rebates and discounts. In emerging markets, prices can be as low as $10-15 per vial.

Profit margins: Branded insulins have gross margins of roughly 70-75%, with net margins around 20-25%, but biosimilar competition and pricing pressures are eroding these margins, especially in developed markets.

R&D investments: Major firms continue to invest in biosimilar insulins and next-generation formulations. For instance, Novo Nordisk has invested over $1.2 billion annually in R&D since 2018, focusing on more affordable biosimilars and novel delivery methods.

Regulatory approvals and pipeline status: Multiple biosimilar NPH insulins hold regulatory approval in Europe and Asia, with more awaiting approval in the U.S. The pipeline contains around 10 biosimilar and follow-on insulin formulations expected to launch over the next 3-5 years.

How Does Patent Status Influence the Financial Landscape?

Patent expirations: Key patents for NPH and human insulin expired between 2015 and 2018, leading to increased biosimilar entry. The impact includes an initial drop in prices by 20-30%, followed by volume-driven growth in sales as healthcare systems adopt lower-cost options.

Current patent protections: Some formulations still benefit from secondary patents or exclusivities that delay generic entry until 2025 or later, sustaining higher prices in certain markets.

Legal battles: Innovators litigate biosimilar filings to extend market exclusivity; such legal disputes can delay generic competition and preserve revenue streams.

What Are Key Market Entry Barriers and Opportunities?

• Barriers: High manufacturing costs, stringent regulatory approval processes, patents securing exclusivity periods, and entrenched provider prescribing habits limit new entrants.

• Opportunities: Growing demand in emerging economies, potential for lower-cost biosimilars, and innovations in delivery devices open avenues for expansion. Companies that can demonstrate comparable efficacy and safety at lower prices gain competitive advantage.

What Is the Outlook for Future Financial Performance?

The overall insulin market is expected to grow moderately through 2030, driven by rising diabetes prevalence and initiatives to improve affordability. Human insulin and NPH will retain a niche in resource-limited settings but face declining dominance in premium markets. Biosimilar entry will intensify price competition, compress margins, and reshape revenue trajectories. Companies investing in biosimilar development, process improvements, and regulatory strategies are positioned for growth.

Key Takeaways

• The insulin market, valued at ~$25.5 billion in 2022, grows at 12% CAGR until 2030, with human insulins' market share remaining stable due to their lower cost.

• Patent expirations have enabled biosimilar competition, reducing prices and creating new revenue streams but exerting pressure on branded product margins.

• Major players continue R&D investment in biosimilars and new formulations, seeking to expand access and reduce costs in emerging markets.

• Pricing strategies vary by geography; U.S. prices for NPH have decreased significantly, while developing markets maintain lower prices.

• Regulatory pathways and patent protections currently shape market entry timing and profitability, with ongoing legal disputes affecting the competitive landscape.

FAQs

1. How are biosimilar insulins affecting the market for NPH and human insulin?
Biosimilars have led to price reductions and increased volume sales, especially post-patent expiration. They have introduced more cost-effective options, expanding access but reducing profit margins for original formulations.

2. Will human insulin and NPH insulin maintain relevance?
Yes, particularly in low-income and resource-limited settings due to their low cost. Their use is declining in high-income markets but remains essential in certain regions.

3. What role does regulation play in the financial prospects of these insulins?
Regulatory approval streamlined for biosimilars facilitates faster market entry, influencing revenue growth and competitiveness. Patent protections and legal challenges also impact timing and profitability.

4. Are there innovations that could boost the revenue of human insulins?
Developments in delivery devices, combination formulations, and biosimilars that demonstrate efficacy at lower costs could increase sales in traditionally stable segments.

5. What is the outlook for companies heavily invested in biosimilar insulin?
They face a competitive environment but can capture market share through pricing advantages and expanded access initiatives, especially in emerging markets.

---

Citations

[1] MarketResearch.com, "Global Insulin Market Size & Forecast," 2022.
[2] IQVIA, "Insulin Market Trends," 2022.
[3] FDA, "Biosimilar Approval Pathways," 2021.
[4] Novo Nordisk, Annual Report 2022.
[5] IMS Health, "Pricing and Prescription Trends," 2022.